Frequently sought out by multinational pharmaceutical, healthcare and medical device clients, DLA Piper covers the full array of life sciences and healthcare services, including M&A transactions, IP, regulatory compliance, investigations and data protection. Spearheading the practice is Ting Xiao in the Shanghai office, specialised in patents, trade secrets, licensing and complex technology transfers. Sammy Fang is an expert in compliance and investigations, while George Wu advises biotechnology companies on IPO matters.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘One of the leading firms supporting Hong Kong IPO with solid connections with the stakeholders. ’
‘George Wu, experienced and resourceful in advising life science clients in the financing, including IPOs.’
Work highlights
Advised a Middle East sovereign fund on its strategic investment in Viva Biotech Holdings, a leading Chinese biotech company listed on the Hong Kong Stock Exchange.
Acting as Underwriter’s International Counsel in connection with the proposed initial public offering (IPO) of Xuanzhu Biopharmaceutical Co., Ltd., on the Main Board of the Hong Kong Stock Exchange under Chapter 18A of the Listing Rules.
Serving as Hong Kong and U.S. legal counsel to the underwriter for the initial public offering (IPO) of 160 Health International Limited on the Main Board of the Hong Kong Stock Exchange.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Ting Xiao
Other key lawyers
Sammy Fang; George Wu